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In this issue of Immunity, Funabiki et al. (2014) have identified in mice a mutation of the IFIH1 gene, encoding
the viral receptor MDA5 that causes constitutive IFN production and fatal autoimmune disease. The authors
show that the autoimmune disease-associated variant of human MDA5 is permanently switched on.Twomajor fields of research, autoimmune
disease and virus infection, converged in
2006 when the interferon (IFN)-induced
helicase 1 gene, IFIH1, encoding a major
pathogen-recognition receptor, MDA5,
for viral infection (Yoneyama et al.,
2004), was associated in one of the
first genome-wide association studies
(GWAS) with risk of the autoimmune dis-
ease type 1 diabetes (T1D) (Smyth et al.,
2006). Binding of double-stranded RNA
(dsRNA) to MDA5 triggers the signaling
molecules IPS-1 (or MAVS), IRF3, and
IRF7, causing transcription of the antiviral
type I IFN (Ivashkiv and Donlin, 2013). This
IFN, which can originate from hematopoi-
etic (dendritic cells and macrophages)
(Funabiki et al., 2014; Ivashkiv and Donlin,
2013) and nonhematopoietic cell lineage
(referenced in Funabiki et al., 2014)
tissues, induces the transcription of hun-
dreds of IFN-inducible genes to contain
the infection. MDA5 function in antiviral
responses is so important that several
viruses have evolved gene functions to
decrease MDA5 activity (Ivashkiv and
Donlin, 2013).
In T1D, the IFIH1 risk allele of a non-
synonymous SNP (rs1990760) encodes
Thr at position 946 in the C-terminal
RIG-1-like domain of MDA5, whereas
the nonpredisposing or disease-protec-
tive allele encodes Ala946, which for this
SNP is the ancestral or ‘‘wild-type’’ (WT)
allele (Smyth et al., 2006; Molineros
et al., 2013) Depending on which side of
the coin you look at, Thr946 provides a
16% increase in T1D risk in 65% of the
British population or Ala946 causes 16%
reduced risk or protection in 35% of the
population. Thr946/Thr946 homozygous
individuals, which account for 42% of
the population, are at 35% increasedrisk of T1D (compared to non-Thr946 or
Ala946-positive carriers) (Smyth et al.,
2006).
Deep resequencing of the IFIH1 gene
from hundreds of T1D patients and con-
trols found low-frequency variants, which
probably result in loss of function, and
were protective for T1D; that is, normal
or increased function of IFHI was predis-
posing to T1D (Nejentsev et al., 2009).
Furthermore, it was shown that the ge-
netic haplotype or chromosome bearing
the Thr946 allele produced more IFIH1
mRNA than the Ala946 haplotype, sug-
gesting that the Thr946 allele has a gain-
of-function effect in its production of
type 1 IFN and/or sensitivity to the effects
of IFN (Downes et al., 2010; Molineros
et al., 2013; Robinson et al., 2011).
Subsequent genetic studies in other im-
mune diseases found the same asso-
ciation in Crohn’s disease, ulcerative
colitis, and psoriasis at genome-wide
significance (immunobase.org), and by
taking a number of studies into account,
the same variant and additional poly-
morphisms in IFIH1 are also, with near
certainty, associated with susceptibility
to systemic lupus erythematosus (SLE)
(Molineros et al., 2013; Ivashkiv and
Donlin, 2013).
Using the now well-established ap-
proach of generating and identifying
chemically-induced mutations in mice
and screening for interesting immune-
and disease-associated phenotypes,
Funabiki et al. (2014) identified a mutation
in the IFIH1 gene, encoding Gly821Ser, in
the Helicase C-terminal domain of MDA5.
They show convincingly that Ser821
causes an SLE-like phenotype in the
mutant mice: nephritis or inflammation of
the kidney, characterized by lymphocyteImmunity 40,infiltration with immunoglobulin and com-
plement deposition and high levels of
interleukin-6 (IL-6), IFN-b, and tumor
necrosis factor-a (TNF-a). There are wide-
spread systemic inflammation effects,
including upregulation of IL-6 and IFN-b
in other organs such as heart and lung.
In the spleen, increased numbers of
effector CD4+ and CD8+ effector T cells,
activated dendritic cells and macro-
phages (producing IL-6), and plasma
B cells were observed, along with
serum anti-nuclear and anti-ds DNA
autoantibodies and hyperimmunoglobuli-
nemia (Figure 1). Nephritis was observed
as early as 6 weeks after birth, and 60%
of the mice died within 24 weeks. Note
that these were heterozygous mice, con-
taining only one copy of the mutant
Ser821 allele: Ser821/Ser821 homo-
zygous mice developed even more
severe inflammation and rarely survived
for 4 weeks after birth. Disease was
completely dependent on the function of
IPS-1, a mitochondrial membrane protein
to which MDA5 binds to trigger the IFN
signaling cascade.
Remarkably, while thismutation knocks
out the ATPase activity of MDA5,
making the receptor unresponsive to
RNA ligands, the mutant molecule is
constitutively active in its function as an
inducer of IFN production owing to a
conformational rearrangement. Very reas-
suringly, in 2009 an independent group
had reported mutations (generated and
analyzed in vitro) in the helicase domain
of human MDA5, for example positions
327 and 826, (Figure 1) that also caused
constitutive activation of the molecule
and continuous, RNA-independent, type
1 IFN production (referenced in Funabiki
et al., 2014).February 20, 2014 ª2014 Elsevier Inc. 167
Figure 1. Gain-of-FunctionMutations ofMDA5Cause Hyperproduction of Type 1 Interferons
and Autoimmunity
Variants of Ifih1 in mice (Gly821Ser) or IFIH1 in human (Ala946Thr) and other variants generated in previous
studies (positions 327 and 826) alter the conformation of this viral RNA recognition intracellular receptor to
make it function constitutively in its role as an inducer of the type 1 IFN pathway. This increase in basal IFN
causes severe SLE-like autoimmune disease in this new mouse model, and the human allele, Thr946, is a
predisposing factor in SLE and other diseases. Chronic IFN production leads to a multitude of immune
phenotypes involving many effector and regulatory components of the immune system with numerous
negative and positive feedback loops. For example, T regulatory cells function to suppress inflammation
and yet type 1 IFN can inactivate these cells and IL-6 inhibits their differentiation. Dendritic cells produce
IFN, and this can activate the dendritic cells in their priming of T cells. In humans, carriage of the Thr946/
Thr946 genotype is neither necessary nor sufficient for the development of autoimmune disease: for dis-
ease to develop, many genes and their predisposing alleles (immunobase.org) are required for acting in a
permissive environment.
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PreviewsMost remarkably, Funabiki et al. go on
to show that the human allele Thr946
has the same activating conformation
and downstream effects, including
constitutive IFN production. The side
chain of Ala946 has been modeled to
make close contact with the helicase
domain (Molineros et al., 2013). Because
carriage of Thr946 by itself in humans
does not cause noticeable lupus-like
symptoms, Thr946 does not have as large
effects as the chemical Ser821 mutation
in their cell assay systems. The present
study will prompt the field to look more
closely at the immune system in Thr946/
Thr946 homozygous individuals versus
Ala946/Ala946 subjects for similar effects.
Analysis of the effects of Thr946 in vivo in
mice engineered for this specific variant
could also be informative. A previous
study has already shown in SLE patients
with anti-ds DNA autoantibodies that the
Thr946 allele increases sensitivity to IFN,
leading to increased IFN-induced gene
expression, including the viral resistance
genes, IFIT1 and MX1 (Robinson et al.,
2011). Serum IFN levels and SLE autoan-168 Immunity 40, February 20, 2014 ª2014 Etibodies are closely correlated suggesting
a causal relationship, supported by
the fact that several other SLE sus-
ceptibility genes function in the IFN
response, including TYK2 and PTPN22
(immunobase.org). Interestingly, this
phenotype was only observed in patients
with autoantibodies (Robinson et al.,
2011), which could be indicative of the
role of many genes and their allelic
variants acting together to produce an
autoimmune-prone genetic background
in which the penetrance or effect of
Thr946 ismore pronounced. Furthermore,
the present study immediately poses the
following question: do rare, more pene-
trant (that is, doubling the risk of disease
or greater) variants of IFIH1 exist in the
human population that by themselves
can cause SLE?
It seems likely that genetically driven,
heightened or chronic type I IFN produc-
tion (or indeed administration of IFN-a in
patients), which has been associated not
only with SLE but also with Sjogren’s syn-
drome, systemic sclerosis, myositis,
rheumatoid arthritis, and most recently,lsevier Inc.with T1D (Ferreira et al., 2014), predis-
poses in humans to increased effector B
and T cell activation, autoantibodies,
and effector cytokines (Ivashkiv and
Donlin, 2013). Patients with SLE and with
other diseases are often positive for an
IFN-induced gene-expression transcrip-
tional signature that can be detected in
blood samples (Ivashkiv and Donlin,
2013). A very similar signature is found in
infants at high risk of T1D before they
develop T1D autoantibodies, and one of
the signature genes is IFIH1 (Ferreira
et al., 2014).
Genetic activation of this disease-asso-
ciated IFN pathway in humans might not
on its own be sufficient to drive autoim-
munity to overt disease, but in com-
bination with other predisposing allelic
variation at an array of genes, for example
those that encode negative regulators of
the immune system functioning to prevent
harmful inflammation and autoimmunity,
such as CTLA-4, PTPN22, GP183 (EBI2),
and IL-10 (immunobase.org), would
make a clinical diagnosis more likely.
However, even if newborn children have
very high doses of autoimmune disease
susceptibility alleles and dysregulated
pathways, the penetrance of such a
genetic profile is very heavily determined
by mostly unknown environmental fac-
tors. For example, frequent viral infections
in very young children could well be a
cofactor, along with an autoimmune
genetic profile, in the development of
subclinical autoimmunity, which might
manifest, again, depending on genes
and environment, many years later in
clinical diagnosis (Ferreira et al., 2014).
At least in mice, it has been reported
that commensal bacteria, the microbiota,
contribute to the maintenance of basal
levels of type 1 IFN production under
physiological conditions (Ivashkiv and
Donlin, 2013). Disturbance of the as-
sembly of a healthy microbiota early in
life, either through host gene variants or
environmental factors such as the use of
antibiotics, diet, and infections, could
well be a factor in immune disease sus-
ceptibility and help explain the familial
clustering of common disorders (referred
to as ‘‘missing heritability’’).
GWAS analyses of common disease
have provided major insights into the
molecules, cells, and pathways involved
in complex, multifactorial disorders.
Although in their infancy, these insights
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Previewsare leading to the identification of thera-
peutic targets and the potential reposi-
tioning of existing drugs with good safety
profiles that modulate the genetically-
validated pathways active in patients or
those at risk of the disease (Plenge
et al., 2013). What clues do these new re-
sults offers for therapeutic strategies in
autoimmune disease? As the authors
discuss, targeting the ATPase activity of
MDA5 might not be that useful, notwith-
standing the reasonable position that
pharmacological inhibition of an essential
antiviral defense molecule might not be
safe. Nevertheless, this study and others
indicate that targeting more downstream
autoimmune events as a consequence
of activating variants of MDA5, such as
inhibition of the IL-6 receptor or of
TNF-a or depletion of (antigen-specific, if
possible) effector B and T cells and/or
improving immunosuppressive T regula-
tory cell functions, such as CTLA-4 or
IL-10, might provide safe therapeutic
approaches. There are obviously already
successful drugs in use clinically for
some of these targets (Plenge et al.,2013). Nevertheless, dose and frequency
of administration of the appropriate drug
in humans (results from mice might not
translate) should be determined in rela-
tively small, open-label, statistically-
designed, mechanistic studies or trials to
investigate immunological efficacy before
launching into large and expensive late-
phase trials. The beauty of this new
single-gene model of autoimmune dis-
ease is that it is caused by a single gene
that is also an autoimmune disease gene
in humans and could therefore be useful
to explore therapeutics preclinically. As
discussed recently (Plenge et al., 2013),
knowledge from human genetics and
genomics studies is, and will continue,
transforming medicine.REFERENCES
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T cells are among the most sensitive of cells, but in this issue of Immunity, Honda et al. (2014) demonstrate
that effector T cells must lose their touch within hours to protect the host from immunopathology.In this issue of Immunity, Honda et al.
(2014) use a delayed-type hypersensitivity
(DTH) model to look at how highly sensi-
tive T cells turn off responses at sites of
inflammation. One of the major problems
that prevented prior studies from being
able to address this issue was asyn-
chrony. The DTH model offered a way to
synchronize the response to antigen and
observe it through the intact ear skin
by two-photon microscopy. Honda et al.
(2014) take advantage of the fact that
recruitment of activated T cells into sites
of inflammation is antigen independent.Therefore, when mice are injected with a
strong adjuvant and a mixture of keyhole
limpet hemocyanin (KLH) and ovalbumin
peptide (OVA) subcutaneously and then
challenged by intradermal injection of
KLH in the ear pinnae 7 days later, the
activation of a few KLH-specific cells in
the dermis leads to recruitment of more
KLH- and OVA-specific cells over the
next couple of days (Honda et al., 2014).
The inflammation induced by the T cells
leads to ear swelling, and the OVA-spe-
cific T cells migrate within the inflamed
dermis in search of antigen. IntravenousOVA peptide introduced at this point
rapidly permeates into the inflamed site
and loads onto I-Ab molecules to activate
OVA-specific T cells, leading to arrest of
the T cells within 1 min. Thus, the activa-
tion process can be synchronized and
the kinetics of the effector cell response
to antigen in an inflammatory setting
could be studied in detail.
Honda et al. (2014) first asked whether
the apparent desensitization of the T cells
was due to loss of antigen, other changes
in theAPCs,or achange in theTcells. They
found that antigen was still active byFebruary 20, 2014 ª2014 Elsevier Inc. 169
